NCT03289910 · OUTCOME

Number of Participants Still Alive at Study Completion

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia · Source last updated 2026-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Up to 7 months

What was measured

Study completion was either death or completion of all protocol-specified activities, whichever came first.

Groups in this outcome

Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)

Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Arm B (Topotecan Hydrochloride, Carboplatin)

Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)	16
Arm B (Topotecan Hydrochloride, Carboplatin)	9

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)	5	Not reported	Not reported	Not reported	Not reported
Arm B (Topotecan Hydrochloride, Carboplatin)	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
5
group Id
OG001
value
5

denoms

counts
group Id
OG000
value
16
group Id
OG001
value
9
units
Participants

description

Study completion was either death or completion of all protocol-specified activities, whichever came first.

groups

description
Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)
description
Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
id
OG001
title
Arm B (Topotecan Hydrochloride, Carboplatin)

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Up to 7 months

title

Number of Participants Still Alive at Study Completion

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice